



## COVID-19 Risk in Cancer Patients Receiving Immunotherapy

Guest Editor:

### Dr. Arjun Singh

Molecular Pharmacology  
Program, Laboratory of Signal  
Transduction, Mortimer B.  
Zuckerman Research Center, 417  
East 68th Street, Memorial Sloan  
Kettering Cancer Center, New  
York, NY 10065, USA

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editor

This article collection focuses on addressing underappreciated issues in the development of treatment strategies, new technologies, and new functional parameters that can better mimic human cancer immunotherapy.

The goal of this research topic is to cover prospective current and novel research on cancer immunotherapy and alternative medical treatment. It may cover (but is not limited to) the following topics:

- Development of novel treatment agents with expected mechanism properties, biocompatibility, and immunotherapy support;
- Development of novel technologies for immunity booster (anti-PD-1/PD-L1 + anti-CTLA-4);
- Bioengineered IMT technologies and designs.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)